Reprogramming protein and immune cell interactions to disrupt cancer
We discover, design and engineer molecules that connect proteins on and within cells to reprogram disease-driving processes or activating immune responses.
Allo-Glues® are small molecule drugs [●] that connect two or more proteins. Drug-induced interaction between an effector protein [●] and a traditionally hard-to-drug target protein [●] can trigger target modulation, inhibition or degradation.
A-Kines® are conditionally active cytokine biologics. Their modified cytokine [●] portion exerts an effect through its receptor only when the A-Kine is connected to a target cell [●] through a cell-specific surface marker [●]. This precision targeting harnesses immune signaling without triggering off-target effects.
Multimodal cell engagers (MCEs) are biologics [●] that connect two or more specified cells, such as an effector cell [●] (e.g., CD8+ T cell or NK cell) with a target cell [●] (e.g., tumor cell). The resulting synapse directs immune cells to modulate or eliminate the target cell. Optional A-Kine components can be included to fine-tune or amplify immune signals.
Allo-Glues® are small molecule drugs [●] that connect two or more proteins. Drug-induced interaction between an effector protein [●] and a traditionally hard-to-drug target protein [●] can trigger target modulation, inhibition or degradation.
A-Kines® are conditionally active cytokine biologics. Their modified cytokine [●] portion exerts an effect through its receptor only when the A-Kine is connected to a target cell [●] through a cell-specific surface marker [●]. This precision targeting harnesses immune signaling without triggering off-target effects.
Multimodal cell engagers (MCEs) are biologics [●] that connect two or more specified cells, such as an effector cell [●] (e.g., CD8+ T cell or NK cell) with a target cell [●] (e.g., tumor cell). The resulting synapse directs immune cells to modulate or eliminate the target cell. Optional A-Kine components can be included to fine-tune or amplify immune signals.
We collaborate with industry and academic leaders across a range of diseases including cancer, autoimmune diseases, and neurodegenerative disorders. These collaborations with world-class institutions validate the disruptive potential and therapeutic promise of our platforms. They also enable us to leverage diverse experiences in next-generation developments of our proprietary OrionisBio™ technology and R&D engines.